| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
The Company shipped eight G4 instruments in the fourth quarter of 2023. Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765 thousand during the fourth quarter of 2022.
"We are proud of the momentum we built throughout 2023, increasing our installed base of instruments and recently launching two high-impact consumable kits: the F3 flow cells and Max Read flow cells," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "In 2024, we look forward to aggressively building our installed base of instruments, bringing exciting new products to market, and delivering exceptional service to our customers."
These preliminary results are based on management's initial analysis of operations for the fourth quarter of 2023 and are subject to further internal review and audit by Singular Genomics' external auditors. Singular Genomics plans to release its full fourth quarter and 2023 financial results in March 2024.
Posted In: OMIC
